预防性人乳头瘤病毒疫苗中国临床应用指南(2025版)  

Preventive Human Papilloma Virus Vaccine Guidelines for Clinical Use in China(2025 edition)

作　　者：中华医学会妇科肿瘤学分会 中国优生科学协会阴道镜和宫颈病理学分会 中华预防医学会肿瘤预防与控制专委会 中国妇幼健康研究会子宫颈癌防控研究专委会 中国癌症基金会全国子宫颈癌防治协作组 中国抗癌协会子宫颈癌专委会 中国医疗保健国际交流促进会妇产健康医学分会 孔北华[2] 马丁[3] 魏丽惠[4] 李明珠[5] 赵方辉[6] 尹如铁[7] 王新宇 丛青[9] 李双[10] 殷爱军[11] 宋坤[11] 隋龙[9] Society of Gynecologic Oncology,Chinese Medical Association;Branch of Colposcopy and Cervical Pathology,China Healthy Birth Science Association;Professional Committee on Cancer Prevention and Control,Chinese Preventive Medicine Association;Specialized Committee on Cervical Cancer Prevention and Control Research,China Maternal and Child Health Research Association;National Collaborative Group for Cervical Cancer Prevention and Treatment,China Cancer Foundation;Committee on Cervical Cancer,China Anti-Cancer Association;Branch of Obstetric and Gynecological Health Medicine,China International Exchange and Promotive;Association for Medical and Health Care;KONG Beihua;MA Ding;WEI Lihui(不详;Department of Obstetrics and Gynecology,Qilu Hospital of Shandong University,Jinan 250012,China;Department of Obstetrics and Gynecology,Tongji Hospital,Tongji Medical College,Huazhong University of Science&Technology,Wuhan 430030,China;Department of Obstetrics and Gynecology,Peking University People's Hospital,Beijing 100044,China)

机构地区：[1]不详 [2]山东大学齐鲁医院妇产科,济南250012 [3]华中科技大学同济医学院附属同济医院妇产科,武汉430030 [4]北京大学人民医院妇产科,北京100044 [5]北京大学人民医院 [6]中国医学科学院肿瘤医院 [7]四川大学华西第二医院/华西妇产儿童医院 [8]浙江大学医学院附属第一医院 [9]复旦大学附属妇产科医院 [10]华中科技大学医学院附属同济医院 [11]山东大学齐鲁医院

出　　处：《协和医学杂志》2025年第2期350-360,共11页Medical Journal of Peking Union Medical College Hospital

基　　金：国家重点研发计划(2021YFC2701202,2021YFC2701203)。

摘　　要：预防性人乳头瘤病毒(human papilloma virus,HPV)疫苗接种是预防HPV感染的有效方法,可降低HPV感染相关疾病的发生。目前国内外临床试验及真实世界研究均表明,预防性HPV疫苗接种是安全的,具有很好的免疫原性、保护效力和保护效果。优先推荐9~26岁女性接种HPV疫苗,重点是9~14岁女孩;同时,推荐27~45岁女性和9~26岁男性接种,倡导男女共防。对于HPV感染或细胞学异常人群、HPV相关病变治疗史人群、遗传易感人群、子宫颈癌发病高风险生活方式人群,以及免疫功能低下人群均推荐预防性HPV疫苗接种。接种HPV疫苗后仍应定期进行子宫颈癌筛查。Prophylactic human papilloma virus(HPV)vaccination is an effective strategy to prevent HPV infection and reduce the incidence of HPV⁃related diseases.Current clinical trials and real⁃world studies globally have demonstrated that prophylactic HPV vaccines are safe,immunogenic,and exhibit robust protec⁃tive efficacy and effectiveness.Priority vaccination is recommended for females aged 9-26 years,with a focus on girls aged 9-14 years.Additionally,vaccination is advised for females aged 27-45 years and males aged 9-26 years to promote gender⁃neutral prevention strategies.Prophylactic HPV vaccination is also recommended for high⁃risk and special populations,including individuals with HPV infection or cytological abnormalities,those with a history of HPV⁃related lesions,genetically susceptible populations,individuals with high⁃risk lifestyle behaviors associated with cervical cancer,and immunocompromised patients.Regular cervical cancer screening remains essential post⁃vaccination.

关 键 词：人乳头瘤病毒 疫苗 临床应用 高风险 特殊人群 

分 类 号：R271.1[医药卫生—中医妇科学] R711.74[医药卫生—中医学]